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24 h following an ultra-distance running event 
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Abstract 
Background: The Mexican Tarahumara are accustomed to running ultra‑distance races. No data exist on the acute 
physiological changes following ultra‑distance running and physiological‑biomarker associations in this population. 
Thus, we aimed to investigate the acute impact (≤ 24 h) on functional and biochemical changes of the cardiac mus‑
cle and biochemical changes associated with kidney function following a 63‑km ultra‑distance race with an altitude 
difference of 1800 m in Mexican Tarahumara athletes.
Methods: Ten Tarahumara male athletes (mean ± SD age = 29.9 ± 6.6 years) volunteered to participate in the study. 
 VO2max was assessed by a sub‑maximal step test individually calibrated combining heart rate and accelerometry. 
Standard transthoracic echocardiography methodology and venipuncture blood tests were carried out at four time 
points: pre‑race, immediately post‑race, 6 h, and 24 h post‑race.
Results: Estimated mean  VO2max was 54.5 (± 8.8) mL O2  min−1 kg−1 and average physiological activity intensity was 
746 (± 143) J min−1 kg −1 (~ 11.5 METs). When compared to pre‑race values, significant changes in left ventricular 
ejection fraction (LVEF) and LV end‑diastolic volume (− 15%, p < 0.001 for both parameters), cardiac output (39%, 
p < 0.001), and maximal longitudinal velocity (− 13%, p < 0.009) were seen post‑race with LVEF also being decreased 
at < 6 h post‑race (− 8%, p < 0.014). Plasma biomarkers mid‑regional pro‑atrial natriuretic peptide, copeptin‑ultra 
sensitive, and high‑sensitivity cardiac troponin T remained significantly elevated at 24 h post‑race, and the two latter 
were inversely associated with LVEF (p < 0.04). Kidney dysfunction was indicated by increased post‑race copeptin‑
ultra sensitive.
Conclusions: The athletes participating in this study had acute transient cardiac dysfunction as assessed by echocar‑
diography but elevated cardiac and kidney biomarkers at 24 h following a 63‑km race with extreme altitude variation.
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Background
The increasing popularity of ultra-endurance sports par-
ticipation has fuelled an ever growing number of reports 
on physiological and biochemical cardiac and kidney dys-
function in elite as well as recreational athletes [1–3]. It 
has been established that engaging in extreme physical 
activities at altitude on a regular basis will result in acute 
changes of heart function at altitude [4]. When looking 
at the heart muscle, the focus has gradually shifted from 
primarily focusing on left ventricular (LV) dysfunction 
and abnormality [5] to also including right ventricular 
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(RV) dysfunction and structural remodeling [2]. While 
LV remodeling as a result of regular endurance training 
seems to be a marker of positive health outcomes rather 
than cardiomyopathy, there is growing evidence that RV 
function may be more profoundly affected by vigorous 
endurance exercise [2].
Similarly, numerous studies have investigated changes 
in biomarkers associated with cardiac and kidney dys-
function as a consequence of ultra-endurance sports 
participation. These have included novel biomarkers 
such as mid-regional pro-atrial natriuretic peptide (MR-
proANP) and copeptin-ultra sensitive (copeptin-us) 
primarily associated with myocardial pressure overload 
and wall-stretch as well as kidney damage/stress and 
hypoxia, respectively [6, 7]. Furthermore, several studies 
have used more conventional biomarkers such as high-
sensitivity cardiac troponin T (hs-cTnT) release primar-
ily associated with hypoxia-induced myocardial damage 
[8, 9]. The exercise-induced release of these biomarkers 
has been intensely discussed in the scientific literature 
with interpretations ranging from being a consequence 
of benign leakage from the cardiac myocyte membrane 
to being myocyte necrosis [10]. There is some evidence 
that aerobic exercise improves renal function due to dif-
ferent mechanisms such as inhibiting the renin–angio-
tensin–aldosterone system or improving renal blood flow 
through modification of dyslipidemia and intra-glomeru-
lar pressure [11–13]. However, intensive endurance exer-
cise may result in rhabdomyolysis-induced acute renal 
dysfunction due to glomerulus degeneration and reduced 
renal blood flow leading to a reduced supply of oxygen 
and energy, resulting in ischemic vascular endothelial cell 
damage [14]. Previous reports covering physiological and 
biochemical changes of the heart and the kidneys have 
ranged from the marathon (42.2  km) to ultra-distance 
races of up to 218.5 km [1, 3, 15], and the average intensi-
ties have ranged from 7.0 to 9.9 km h−1. However, except 
for one recent investigation focusing on cardiac and kid-
ney biomarkers [7] following ultra-distance running at 
moderate altitude in flat terrain in Mexican Tarahumara 
runners, none of these studies have reported results from 
indigenous American athletes.
For more than a century, the Tarahumara who reside in 
northern Mexico have been known for their prowess of 
ultra-distance running—here defined as distances longer 
than the marathon race (42.2 km)—in the Sierra Madre 
Occidental mountains (also known as the Sierra Tarahu-
mara) with steep canyons deeper than 1800 m [16]. Early 
studies have reported moderate running intensity in the 
Tarahumara when engaging in long-distance running [17, 
18]. More recently, we reported high daily physical activ-
ity in rural Tarahumara [19] indicating generally high 
activity levels in this population which may be introduced 
during childhood and persist throughout life. Thus, we 
aimed to study the combined acute impact (≤  24 h) on 
and association between physiological and biochemical 
changes of the cardiac muscle following a 63-km ultra-
distance race with an altitude difference of 1800 meters 
in Tarahumara athletes who have life-long adaptation to 
long-distance running and physical activity in mountain-
ous terrain.
Methods
Ten adult Tarahumara men from the village of Chogu-
ita, Chihuahua, who participated in a 63-km race of the 
Ultramaratón de los Cañones in the state of Chihuahua, 
Mexico, volunteered to participate in the study. The 
number of included participants was based on avail-
ability of subjects participating in the 63-km race at the 
time of the study. The event took place in July 2012, and 
began at 6:00 a.m. in the town of Guachochi at an alti-
tude of ~ 2400 m; the route was a loop including a drop 
of ~ 1800 m into the bottom of the Barranca de la Sin-
forosa from where the runners had to return. All pre-race 
measurements were carried out on the day before the 
race. Through a contact person, the participants were 
instructed not to do strenuous exercise 3 days prior to the 
pre-race measurements, as well as abstain from smoking, 
alcohol consumption, and drinks containing caffeine on 
the day of the pre-race measurements as well as during 
the 24-h post-race period. Height and weight were meas-
ured to the nearest 0.1 cm and 0.1 kg, respectively, with 
the participant wearing minimal clothing, and body mass 
index (weight in kg/height in  m2) was derived.
Systolic and diastolic blood pressures were measured 
using the auscultatory method (VSG-3 model, Phillips, 
Eindhoven, the Netherlands). Blood pressure was meas-
ured three times on the right upper arm with the par-
ticipant seated and following 15 min of rest with 2 min 
in-between each measurement. Mean blood pressure 
was calculated from the last two measurements. Elevated 
blood pressure was defined as systolic blood pressure 
≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm 
Hg [20].
Glycated hemoglobin (HbA1c) and hemoglobin (Hb) 
levels were determined by capillary blood. HbA1c was 
analyzed using an automated boronate affinity assay 
which minimizes interference from other Hb variants 
and derivates analyzed by an Afinion AS100 Analyzer 
(Alere-Axis Shield PoC, Oslo, Norway). Hb was analyzed 
by a modified azide-methaemoglobin reaction [21] using 
a Hb 2011 device (HemoCue AB, Ängelholm, Sweden). 
Anemia was defined as blood Hb below 13 mg/dL.
VO2max and race energy expenditure were estimated 
using a combined uniaxial accelerometer and heart rate 
(HR) sensor (Actiheart, CamNtech Ltd, Cambridge, UK) 
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attached to the chest on two ECG electrodes (Unomedi-
cal A/S, Birkerød, Denmark). One day prior to the race, 
each participant performed an 8-min step test, stepping 
up and down to a voice prompt on a 21.5-cm-high step 
(Reebok, Lancaster, UK) using a sub-maximal ramped 
protocol [22]. The monitor was then initialized to record 
at 15-s intervals and participants wore the monitor 
continuously for the following 24  h (including the race 
period). For further details of the step test and physical 
activity monitoring, see [7].
Following the race, each participant did a quantita-
tive physical activity and competition personal history in 
Additional file 1: Questionnaire (in Spanish), specifically 
prepared for the study.
A standard 12-lead electrocardiography (ECG) was 
performed using a Medi Trace, ver. 5.2 (Medi Core, Mex-
ico City) pre- and post-race. The ECG was read by an 
experienced cardiologist, blinded to participant demo-
graphic and race data.
A standard transthoracic echocardiography was per-
formed at pre-race (baseline), 30  min post-race, 6  h 
post-race, and 24  h post-race using at  Philips® Cx50 
Ultrasound system, equipped with the S5-1 transducer. 
The patient was placed in the left lateral decubitus posi-
tion and at least three cycles were recorded triggered 
to the ECG at end-expiration. Analysis of the recorded 
imaging was performed blinded to exercise efforts using 
the Philips Excelera version R3.3L1 and Qlab software 
version 9.1, applying the QMC solution for deformation 
analysis. RV and LV chamber dimensions were measured 
according the current guidelines [23]. LV mass was cal-
culated according to the formula: 0.8*(1.04*[{LV internal 
dimension-diastole  +  posterior wall thickness at end 
diastole + superior wall thickness at end diastole)3 − (LV 
internal dimension-diastole)3]}, and then indexed to body 
surface area. Cardiac deformation was assessed from 
tracing the LV wall and septum in the apical 4-, 2-cham-
ber and long-axis views in 17 segments [23]. The global 
longitudinal strain of the RV free wall was calculated as 
the mean of the basal, mid, apical, and apex segments in 
the apical 4-chamber view as recommended [23].
Ten mL blood was collected at each time point: pre-
race (baseline), < 5 min post-race, 6 h post-race, and 24 h 
post-race. The blood samples were drawn by standard 
venipuncture into BD-Vacutainer® tubes containing lith-
ium heparin. All the samples were centrifuged, plasma 
transferred to cryogenic tubes, and frozen in aliquots at 
− 80 °C until transported on dry ice to Copenhagen Uni-
versity Hospital (Rigshospitalet), Denmark for analyses.
Plasma concentrations of hs-cTnT, creatine kinase 
(CK), and CK isoform myocardial band (MB), creati-
nine, high-sensitivity C-reactive protein, iron, hapto-
globin, lactate dehydrogenase (LDH), albumin, sodium, 
and potassium were measured using the fully automated 
Roche/Hitachi MODULAR SYSTEMS platform (Roche 
Diagnostics GmbH, Mannheim, Germany); all analyses 
were accredited by the national accreditation body in 
Denmark (DANAK). MR-proANP and copeptin-us con-
centrations were measured using the Kryptor Compact 
Plus platform (Thermo Fisher Scientific, BRAHMS, Hen-
nigsdorf, Germany); the validation of the two analyses 
has been reported previously [24, 25].
Statistics
All background and descriptive results are given as mean 
(SD). Within and between subject variation of echocar-
diographic measurements, plasma markers and ECG 
were calculated using linear regression analyses to test 
for associations between exposure and outcome variables 
as well as between different outcome variables. Age was 
used as explanatory variable, and in all linear regression 
analyses the pre-race (baseline) results were used as ref-
erences. Multivariate regression analyses were performed 
in order to rule out the possibility that pre-race LVEF 
level confounded the relationship between LVEF and 
 VO2max and in order to determine if the post-race LVEF 
results were explained by high or low  VO2max (study 
participants were allocated to two groups of five each, 
under and above the median of 52.5 mL O2  min−1 kg−1, 
respectively). The latter multi-regression analysis tested 
an interaction between time of post-race LVEF levels and 
 VO2max group including pre-race LVEF in the analysis as 
well. Plasma marker results have been adjusted for albu-
min as a proxy of hydration in order to present hydra-
tion-independent results. In case of participants having 
plasma values below the detection limit for a plasma 
marker, data have been presented as median (IQR). A 
value between 0 and the detection limit was randomly 
chosen and used in the regression analysis. After the first 
post-race measurements, two of the ten study partici-
pants failed to show up for the last two post-race meas-
urements. As a result, all analyses have been carried out 
based on ten participants for the first two measurements, 
and based on eight participants for the last two measure-
ments. p  <  0.05 was considered statistically significant. 
All analyses we done with Stata 13.1 Intercooled version 
(Stata Corp, College Station, TX).
Results
Mean age of the subjects was 29.9 (± 6.6) years, rang-
ing from 22 to 45  years of age. No abnormalities, i.e., 
valve disease or non-training-related ECG changes 
were observed during the pre-race echocardiographic 
and ECG tests with small, statistically non-significant 
fluctuations of ST segment elevation or depression 
post-race (results not shown).
Page 4 of 10Christensen et al. Extrem Physiol Med  (2017) 6:3 
Background characteristics are presented in Table  1. 
Estimated mean  VO2max was 54.5 (±  8.8) mL  O2 
 min−1  kg−1, with the average physiological (activity) 
intensity during the race being 746 (± 143) J min−1 kg−1 
(~ 11.5 METs including resting energy expenditure) or if 
expressed relative to individual  VO2max approximately 
72 (± 6) % of estimated  VO2max. Mean duration of race 
time was 418.3 (± 42.5) min, and mean absolute intensity 
was 9.1 (±  0.9) km  h−1. Estimated  VO2max, HR meas-
ures, and absolute and relative intensities of the 63-km 
race are presented in (Table 2).
Pre-race mean relative LV mass was 106 g m−2 (± 23), 
with all participants being within the reference range 
of 49–115  g  m−2 according to [23] except for one, who 
had a mildly increased LV mass at 122 g m−2. Mean LV 
ejection fraction (EF), LV end-diastolic volume, and car-
diac output showed the most marked changes compared 
to the pre-race values with all 30 min post-race changes 
(p < 0.001), and for the former 6 h post-race change also 
being significantly different (p  <  0.014) (Fig.  1). Mean 
post-race cardiac deformation measurements LV global 
longitudinal strain (GLS) and estimated RV GLS did not 
show any significant changes compared to mean pre-
race values (Fig.  2). Other echocardiographic measure-
ments are shown in (Table 3) with post-race reduction of 
maximal longitudinal velocity (RV S’) (30 min, p < 0.009) 
and LV velocity time integral (30  min, p  <  0.007 and 
6  h, p  <  0.041) and subsequently normalized. Post-race 
HR increased (30 min, p < 0.001 and 6 h, p < 0.002) and 
stroke volume decreased (30  min, p  <  0.001 and 6  h, 
p = 0.057).
For the plasma biomarkers, one participant was below 
the detection limit for hs-cTnT of 3  ng/L and six par-
ticipants were below the detection limit for haptoglobin 
0.2  g  L−1 at one or more time points. Mean concentra-
tions of novel biomarkers MR-proANP and copeptin-us 
showed marked changes at < 5 min post-race compared 
to pre-race concentrations (p < 0.001), and the latter was 
also significantly different from the pre-race concentra-
tion at 6 h and 24 h post-race (p < 0.001) as was hs-cTnT 
(Fig. 3). Several other biomarkers showed mean post-race 
concentrations significantly different from the pre-race 
concentrations including at 24 h post-race (Table 3).
LVEF and LV GLS were significantly associated 
(ß = − 0.8, within-individual R2 = 0.18, p < 0.02). LVEF 
was significantly associated with copeptin-us (ß = − 0.8, 
within-individual R2  =  0.30, p  <  0.039), hs-cTnT 
(ß = − 2.9, within-individual R2 = 0.36, p < 0.001), but 
no statistically significant age-adjusted correlations were 
found between neither copeptin-us nor hs-cTnT with 
RV GLS or LV GLS. Of these biomarker and echocardi-
ography measurements, only LVEF was significantly cor-
related with estimated  VO2max (ß = − 0.34, p < 0.007), 
while none of these parameters were significantly cor-
related with duration of race time (data not shown). 
Pre-race LVEF could not explain the post-race LVEF 
development (p  =  0.734), and no interaction between 
 VO2max group (<  52.5 and >  52.5 estimated  VO2max) 
and post-race LVEF measurement was found (p = 0.854), 
and the inverse relationship between LVEF and  VO2max 
was no longer statistically significant (p = 0.096). When 
presented separately in a similar multivariate regression 
analysis (co-variables: post-race LVEF, pre-race LVEF, 
and age) for the two  VO2max groups, the post-race time 
points showed similar albeit non-significant results, i.e., 
high  VO2max (ß  =  0.12, p  =  0.150) and low  VO2max 
(ß  =  0.17, p  =  0.150). Race time and  VO2max were 
inversely correlated (ß = − 1.40, p < 0.001).
The HR-corrected QT interval at 24  h post-race 
increased by 28 ms (p < 0.011). Other time intervals did 
not change significantly post-race (Table 3).
Discussion
Several functional cardiac measurements as well as 
plasma biomarkers showed that the participants of this 
study had acute and sub-acute exercise-induced impact 
on cardiac function. However, it is of note that several 
cardiac and kidney biomarkers remained elevated at 24 h 
post-race. Furthermore, running intensity was relatively 
high at 72%  VO2max.
For cardiac output (increase) and LV end-diastolic 
volume (decrease), the values were only altered imme-
diately post-race. As expected, cardiac output increase 
was due to an increase in HR but independent of a sig-
nificant decrease in stroke volume. LVEF functionality 
decreased immediately and at 6 h post-race, and  VO2max 
Table 1 Background characteristics of male Tarahumara 
runners (n = 10) presented as mean (SD)
a n = 9
b Blood pressure measured with subject in sitting position ≥ 15 min of rest
Variable Mean SD Range
Age (years) 29.9 6.6 22–45
Height (cm) 162 0.1 155–177
Weight (kg) 54.2 5.7 46.0–64.6
Body mass index (kg/m2) 21.2 1.7 18.7–24.1
Waist circumference (cm) 76.5 4.5 68.2–83.4
Body fat (%)a 10.6 1.5 8.0–12.7
Body surface area  (m2) 1.22 0.15 1.00–1.47
Systolic blood pressure (mmHg)b 105 9 96–126
Diastolic blood pressure (mmHg)2 64 7 56–78
Glycated hemoglobin (%) 5.7 0.2 5.3–5.9
Hemoglobin (g/dL) 15.7 1.5 12.4–18.0
Hematocrit (%) 47.2 4.6 37.2–54.0
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was not significantly associated with the decreased post-
race LVEF in contrast to other studies [26]. A possible 
mechanism to this feature relates to the volume overload 
of LV presuming that it is greater with higher  VO2max. 
Initially, the preload is increased with almost maximal 
use of the Frank-Starling mechanism with some increase 
in systolic aortic pressure. The ejection fraction would 
remain the same as these two changes annul each other. 
Thereafter, the left ventricle dilates and becomes hyper-
trophic resulting in chronic overload which produces 
further elongation of myocardial fibers. Eventually, the 
cardiac muscle fails to maintain a match between pre- 
and afterload following which ejection fraction declines 
[26]. The possible mechanism just described refers to 
LVEF during exercise, but hardly remains a factor in the 
acute phase following cessation of exercise, i.e., until 
30  min post-exercise when the first post-race echocar-
diographic scanning was carried out. Nevertheless, there 
could be other regulatory mechanisms which may have 
contributed to the decreases in LV function, including 
also the sub-acute post-race decrease in LV end-diastolic 
Table 2 Estimated  VO2max, heart rate measures, abso-
lute and relative intensities of 63-km running, and history 
of running competition in Tarahumara athletes (n = 10) 
presented as mean (SD)
* Number of running competitions within last year with distance/time ranging 
from 42 to 63 km to 24-h traditional kick-ball race estimated at 150–200 km 
(based on answers from 8 participants). One participant reported having 
experienced hematuria
a Estimated maximal heart rate according to Tanaka equation
b Net heart rate is heart rate above sleeping level
c Activity intensity during race without resting energy expenditure
Variable Mean SD Range
Sleeping heart rate (bts min−1) 51 3 47–58
Estimated maximal heart rate (bts min−1)a 187 4 177–193
Estimated  VO2max  (mlO2 min
−1 kg−1) 54.5 8.8 40.9–70.1
Race time (min) 418.3 42.5 351–485
Absolute intensity (km h−1) 9.1 0.9 7.8–10.8
Net heart rate during race (bts min−1)b 103 8.0 90–116
Physiological intensity (J min−1 kg−1)c 746 143 500–1002
Relative intensity (%) 72 6 61–79
Running competitions (n)* 8 0–25
Fig. 1 Within subject variation of left ventricular ejection fraction (%), left ventricular end‑diastolic volume (mL), and cardiac output (L min−1) 
with age as explanatory variable, using the baseline values as the references was done by repeated measurements (mean (95% CI)) at time points 
30 min, 6 h, and 24 h after running 63 km. *Denotes p < 0.01; **Denotes p < 0.05
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volume. These include a down-regulation of cardiac 
β-receptors mediated by elevated catecholamines during 
endurance exercise [27, 28] or alterations in myofilament 
sensitivity to calcium [29] among others. It is of note that 
the decrease in LVEF in the presence of decreased sys-
tolic blood pressure which remained significant up to 
24 h post-race reflects depressed cardiac contractility. In 
combination, the decrease in LVEF and LV end-diastolic 
volume can be interpreted as “cardiac fatigue” [30] which 
is a common feature following endurance events as dem-
onstrated in several other studies focusing on prolonged 
exercise of different distances [31, 32]. Furthermore, in 
spite of the non-significant changes in LV GLS following 
the ultra-distance race, the changes in LV GLS and LVEF 
were significantly associated. There may have been a lack 
of statistical power to show a post-race within-individ-
ual change in cardiac strain despite the acute change in 
preload.
Plasma copeptin-us—a stable C-terminal portion of 
arginine vasopressin precursor—was inversely associated 
with post-race LVEF. As a marker of dehydration and 
hypoxia, elevated plasma copeptin-us indicates that post-
race LVEF could partly be explained by dehydration as 
well as a state of hypoxia. Evidence for dehydration was 
also supported by the decrease in mean LV end-diastolic 
volume 30 min post-race and by mean velocity time inte-
gral which was decreased up to 6  h post-race. Further-
more, the significant increase in mean plasma albumin at 
<  5  min post-race by 4.5  g  L−1 is strong evidence for a 
state of dehydration.
Hypoxia may also be assessed by plasma hs-cTnT 
which showed an inverse association with LVEF; this 
further suggests a state of cardiac hypoxia as a conse-
quence of the ultra-marathon race performed under 
extreme altitude-changing conditions. This is in con-
trast to earlier studies which did not find any associa-
tions between changes in LVEF and post-race cardiac 
troponins [2, 5] despite an increase in cardiac troponins 
in various ultra-exercise events lasting up to ~ 30 h of 
duration and one [5] being a 100 miles foot race cover-
ing altitude differences comparable to the current study. 
A likely explanation for this discrepancy is a difference 
in exercise intensity and/or altitude change during exer-
cise with 1800 m of especially uphill running in the pre-
sent study as a major influence on cardiac strain and 
functionality.
It is of note that except for mean RV S’ which decreased 
by ~  13% 30  min post-race, none of the RV functional 
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measurements were significantly altered post-race. Pre-
vious reports did, however, show substantial exercise-
induced RV dysfunction in endurance athletes [2, 15, 33, 
34], and in some cases, RV dysfunction persisted up to 
1 month following an endurance exercise event [34].
Based on the absolute as well as relative intensity 
(9.1  km  h−1 and 72%, respectively), the athletes in our 
study did race at a the lower end of high intensity (≥ 70%) 
which is a little higher than we had expected based on 
previous reports [7] but also based on the estimated 
 VO2max of 54.5  mLO2·min−1·kg−1. The latter indicates 
that the intensity of their regular exercise pattern would 
be of moderate intensity as reported  VO2max were 
similar (~ 58  mLO2 min−1 kg−1) in other amateur ultra-
endurance athletes [3]. It is noteworthy that Neilan et al. 
[35] demonstrated that the majority of the most marked 
cardiac structure and function as well as cardiac bio-
markers were observed in athletes training less than 35 
miles week−1 before a marathon race, i.e., at high inten-
sity. Male Tarahumara in general have most likely had 
life-long exposure to ultra-distance running at low to 
moderate intensity suggesting that exercise intensity may 
be more important in acute and chronic RV dysfunction 
than exercise duration per se. Nevertheless, it is impor-
tant to add that combined age and sub-maximal derived 
 VO2max has an uncertainty of ± 12  O2 min−1 kg−1 [22, 
Table 3 Alterations of echocardiographic measures, plasma markers, and electrocardiogram following 63 km of running 
at moderate-to-low altitude in male Tarahumara (n = 10) presented as mean (95% CI)
TAPSE tricuspid annular plane systolic excursion; RV S’ right ventricular annular maximal longitudinal velocity; LV outflow VTI left ventricular velocity time integral; LV 
SAX GCS left ventricular parasternal short-axis global circumferential strain; LDH lactate dehydrogenase; creatine kinase-MB creatine kinase isoform myocardial band; 
hs-CRP high-sensitivity C-reactive protein; SBP systolic blood pressure; DBP diastolic blood pressure
a Analyses age-adjusted
b First post-race echocardiographic measurement carried out 30 min post-race
c First post-race blood samples collected < 5 min post-race
d First post-race electrocardiogram measurement carried out < 40 min post-race
Parameter Pre-race Post-race changes (mean values (95% CI) with statistical differences from pre-race value)
< 5-min/30-min p value 6-h p value 24-h p value
Echocardiographya,b
 TAPSE (cm) 2.6 (2.4; 2.9) − 0.2 (− 0.5; 0.1) 0.257 − 0.1 (− 0.4; 0.2) 0.654 0.4 (0.1; 0.7) 0.007
 RV S’ (cm s−1) 15.5 (14.3; 16.7) − 2.1 (− 3.6; − 0.5) 0.009 1.0 (− 0.6; 2.6) 0.233 0.8 (− 0.9; 2.5) 0.330
 LV outflow VTI (cm) 22.1 (20.3; 23.8) − 2.6 (− 4.6; − 0.7) 0.007 − 2.2 (− 4.3; − 0.1) 0.041 − 0.4 (− 2.5; 1.7) 0.699
 LV SAX GCS (%) 17.8 (15.0; 20.6) − 1.7 (− 5.1; 1.6) 0.303 2.5 (− 1.4; 6.3) 0.206 4.3 (0.7; 7.9) 0.019
Plasma  biomarkersa,c
 LDH (U L−1) 102.8 (19.3; 186.3) 259.9 (176.4; 343.4) 0.004 209.4 (116.6; 302.1) 0.065 270.3 (177.5; 363.0) 0.004
 Creatine kinase (U L−1) 140.0 (66.2; 213.8) 2737 (2683; 7267) < 0.001 5535 (2298; 8772) < 0.001 5380 (2234; 8527) < 0.001
 Creatine kinase‑MB (µg L−1) 3.1 (1.3; 4.8) 62.5 (26.5; 98.6) < 0.001 70.6 (27.0; 114.3) < 0.001 56.3 (21.5; 91.0) < 0.001
 Creatine kinase ratio 2.3 (1.3; 3.3) 0.4 (− 1.0; 1.8) 0.573 − 0.9 (− 2.3; 0.6) 0.258 − 1.0 (− 2.5; 0.5) 0.179
 Creatinine (µmol L−1) 64.9 (50.0; 79.8) 88.1 (73.2; 103.0) 0.002 88.6 (72.5; 104.7) 0.004 69.6 (53.5; 85.7) 0.565
 hs‑CRP (mg L−1) 0.8 (0.1; 1.4) 1.2 (0.3; 2.1) 0.336 9.9 (1.7; 18.1) < 0.001 15.8 (2.8; 28.8) < 0.001
 Iron (µmol L−1) 15.1 (12.3; 17.9) 13.5 (11.7; 15.2) 0.226 7.0 (5.4; 8.6) < 0.001 20.5 (17.4; 23.6) 0.004
 Haptoglobin (g L−1) 0.9 (0.7; 1.1) 0.3 (0.2; 0.5) <0.001 0.4 (0.2; 0.6) < 0.001 0.8 (0.6; 1.0) 0.165
 Sodium (mmol L−1) 138 (131; 146) 128 (121; 135) 0.020 141 (133; 149) 0.549 152 (144; 160) 0.005
 Potassium (mmol L−1) 4.3 (3.8; 4.7) 4.6 (4.1; 5.0) 0.354 4.3 (3.8; 4.8) 0.917 4.5 (4.0; 5.0) 0.572
 Albumin (g L−1) 46.8 (44.7; 48.8) 51.4 (49.3; 53.4) < 0.001 47.0 (44.7; 49.2) 0.877 44.1 (41.8; ; 46.3) 0.045
Electrocardiograma,d
 PQ interval (ms) 154 (147; 162) − 4 (− 12; 3) 0.254 0.0 (− 8; 8) 0.975
 QRS complex (ms) 86 (81; 91) − 2 (− 6; 1) 0.230 − 2 (− 6; 1) 0.192
 QTc (ms) 405 (390; 419) 19 (− 2; 40) 0.073 28 (6; 49) 0.011
Hemodynamicsa,d
 Heart rate (bts min−1) 56 (51; 61) 33 (26; 40) < 0.001 11 (4; 18) 0.002 4 (− 3; 11) 0.302
 Stroke volume (L min−1) 7.1 (6.6; 7.7) − 2.0 (− 2.6; − 1.3) < 0.001 − 0.7 (− 1.3; 0.2) 0.057 1.7 (− 0.5,0.9) 0.612
 SBP (mmHg) 105 (99; 111) − 6 (− 13; 19 0.008 − 7 (− 15; 0.0) 0.043 − 8 (− 15; − 1) 0.030
 DBP (mmHg) 64 (60; 67) 1 (− 3; 6) 0.613 − 6 (− 11; − 1) 0.018 − 9 (− 14; − 4) < 0.001
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36] making a validation of the 8-min step test high prior-
ity for the sake of interpretation.
In support of an exacerbated strain on the cardiac mus-
cle when competition is conducted in terrain of altitude 
variation with descent and ascent compared to no alti-
tude variation was our finding on plasma MR-proANP. 
It remained significantly elevated in the present study at 
24  h post-race. However, in a study we conducted in a 
group of male Tarahumara running 78 km on a flat route 
at 2400 meters above sea level and carried out at similar 
absolute but slightly lower relative intensity compared to 
the present study, post-race elevated MR-proANP was 
cleared at 1 h post-race [7].
Renal function was also compromised as a result of the 
physical exertion the runners underwent. Apart from 
plasma copeptin-us—which had increased ~  tenfold 
immediately post-race and remained significantly ele-
vated at 6 h post-race—plasma creatinine also remained 
elevated at the 6 h post-race time point with an increase 
of ~  35%. These results confirm a post-race increase 
in plasma copeptin-us and creatinine similar to what 
we reported from an earlier ultra-distance race in male 
Tarahumara [7] as well as shown in several other stud-
ies based on distance races ranging from 42 to 100  km 
[1, 15, 37]. Likewise, copeptin-us and creatinine increase 
could have been caused by dehydration. Furthermore, 
one participant reported having previously experienced 
hematuria following a race which suggests that at least 
some of the Tarahumara runners acutely overexert kid-
ney functionality.
Several other plasma biomarkers remained signifi-
cantly elevated at 24 h post-race including CK (~ 40-fold 
increase) CK-MB (~ 20-fold increase) and LDH (~ three-
fold increase) which indicates severe skeletal muscular 
damage that could have been exacerbated by eccentric 
muscle contractions when going downhill. This is sup-
ported by laboratory-based results of increased serum 
CK up to 48 h following 45 min of downhill running [38].
It is of note that one participant had elevated blood 
pressure at pre-race measurement. However, without 
follow-up measurements in a clinic we would be reluc-
tant to define the participant as having hypertension. 
Furthermore, “white coat hypertension” caused by appre-
hension is a likely cause of the elevated blood pressure. 
Furthermore, another participant was anemic, which is 
a common trait in individuals living under constrained 
dietary conditions like the Tarahumara. It is likely that 
the anemic state negatively affected the performance of 
Fig. 3 Within subject variation of mid‑regional pro‑atrial natriuretic peptide (pmol L−1), copeptin‑ultra sensitive (pmol L−1), and high‑sensitivity car‑
diac troponin T (ng L−1) with age as explanatory variable, using the baseline values as the references was done by repeated measurements (mean 
(95% CI)) at time points < 5 min, 6 h, and 24 h after running 63 km. *Denotes p < 0.01
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this individual and thereby the results of the echocardio-
graphic and biomarker measurements.
We acknowledge several limitations to this study. In spite 
of an attempt to include a non-Tarahumara control group 
participating in the same race, we did not succeed primarily 
due to the time line with the 24-h follow-up measurements. 
We did not obtain post-race body weight measures as an 
indication of dehydration in spite of the useful information 
from a variation of this parameter [39]. Instead, we used 
albumin as a marker of dehydration and adjusted all plasma 
biomarker analyses for albumin in order to present bio-
marker results not confounded by dehydration.  VO2max 
was estimated using the HR as a proxy for oxygen uptake 
based on the linear relationship between  VO2-uptake and 
HR. Furthermore, the protocol was sub-maximal using 
predicted maximal HR according to Tanaka et al. [36] for 
the assessment of  VO2max. This indirect methodology may 
have resulted in a ± 12% deviation compared to an indirect 
calorimetric measurement. Lastly, the low number of study 
participants (n = 10) may have introduced a statistical type 
II error, and the generalizability to other Tarahumara must 
therefore be done with caution.
Conclusion
Following a 63-km race with extreme altitude variation 
run at high intensity, the Tarahumara athletes partici-
pating in this study showed acute, transient cardiac and 
kidney dysfunction as assessed by echocardiography and 
plasma biomarkers. LV dysfunction was more apparent 
than RV dysfunction, but both were normalized < 24 h, 
while several plasma biomarkers remained elevated at 
24  h post-race. The lack of transient RV dysfunction 
warrants further studies with longer running exposure 
in order to investigate a possible threshold for com-
promising RV function in this population and possible 
explanatory mechanisms. In addition, possible perma-
nent cardiac dysfunction following life-long exposure to 
ultra-distance running as practiced among the Mexican 
Tarahumara should be studied with a non-Tarahumara 
reference group who have taken up ultra-distance run-
ning in adulthood; this way the life-course duration of 
ultra-distance running as an exposure factor for cardiac 
dysfunction can be elucidated and thereby further qualify 
medical advice for ultra-endurance athletes.
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